ABSTRACT
The [4619] [4620] [4621] [4622] [4623] [4624] [4625] [4626] [4627] [4628] [4629] 1996) C ORTICOTROPIN RELEASING factor (CW) is a 41 amino-acid peptide that has been associated with several different endocrine, physiological, neurochemical, and behavioral responses (for reviews see Refs. 1 and 2). It is therefore not surprising to find a wide distribution of this neuropeptide throughout the central nervous system (CNS); cell bodies and fibers that stain positive for CRF are heterogenously but selectively distributed within several distinct structures including the isocortex, central nucleus of the amygdala (CeA); bed nucleus of the stria terminalis; arcuate, periventricular, supraoptic, suprachiasmatic, preoptic, and paraventricular nucleus of the hypothalamus (PVN); and brainstem nuclei (i.e. locus coeruleus, dorsal vagal complex, and parabrachial nucleus) (3-S).
However, despite this broad distribution within the CNS, only few CRF groups of neurons appear to respond to stress. Indeed, acute immobilization stress caused an increase in CRF messenger RNA (mRNA) levels within the CeA and PVN (9), whereas chronic footshock stress has been shown to significantly increase CRF mRNA in both Barrington's nucleus (a pontine micturition center) and the PVN (10). Interestingly, although glucocorticoids negatively regulate CRF mRNA within the PVN (lo-12), it has been reported that CRF mRNA levels in the CeA increase after chronic corticosterone treatment (13). In a very extensive study, Rivest et al. (14) demonstrated that among all the CRF-expressing regions of the brain, the PVN was the only structure exhibiting an increase in CRF transcriptional activity after a systemic immunogenic stress. In fact, of all these aforementioned structures, the PVN represents perhaps the most widely recognized and studied population of CRF neurons within the CNS. These cell bodies, which project primarily to the median eminence to release CRF into the hypothalamichypophysial portal system, are the main source of the neuroendocrine CRF involved in triggering the synthesis and release of ACTH from the adenohypophysis (5, 15, 16).
However, these CRFergic cells of the PVN are not the only neurons of the brain involved in the regulation and adaptation of the neuroendocrine response to stress. There are several neurochemical systems that can participate in the regulation of neuroendocrine CRF neurons including the central CRF system itself. Intracerebroventricular (icv) injection of CRF activates transcription of c-fos mRNA (an indicator of cellular activation) within CRF-immunoreactive neurons of the rat PVN, raises relative levels of PVN CRF mRNA, and enhances the release of the neuropeptide into the infundibular system (17, 18) . This activation of CRF-PVN neurons by exogenous CRF may represent a positive ultra-short feedback of selective neuroendocrine cells (19). This claim is further supported by neuroanatomical studies in which CRF perikarya located in the parvocellular division of the PVN receive synaptic contacts with CRF nerve terminals (20). Furthermore, another query is whether this autoregulatory mechanism is mediated through a specific CRF receptor subtype.
The recent cloning of different CRF receptor subtypes is a fascinating new development because it provides the opportunity to better investigate the sites of action of the neuropeptide within the brain. There are presently two distinct CRF receptor types that have been cloned and localized with significant differences in their pharmacological profile and distribution pattern (21). The first to be isolated was the CRF type 1 (CRF,) receptor complementary DNA (cDNA) by Dr. Vale's group for both the rat (22) and human (23) brain. Only recently has the CRF type 2 (CRF,) receptor cDNA been cloned and characterized in the rat (21, 24) and human (25) brain. Moreover, in the rat brain, this CRF, receptor exists in two alternatively spliced forms, CRF,, and CRF,,, each having a different distribution (26). Although quite similar in their central distribution, the CRF, receptor mRNA is low or undetectable in several regions associated with CRF mRNA (27). For example, within hypothalamic regions known to have elevated basal CRF mRNA levels such as the PVN, very low and diffuse levels of the CRF, receptor mRNA were measured (27) . Interestingly however, is the fact that either an immune challenge or an immobilization stress could induce a very selective and strong activation of the CRF, receptor mRNA within hypothalamic nuclei involved in the regulation of neuroendocrine functions, particularly the parvocellular division of the PVN (28). This fact, taken together with CRF's ability to activate its own gene expression selectively within the PVN (18), further supports the existence of an ultra-short loop positive feedback mechanism through which CRF may modulate its own biosynthesis. However, whether these CRF-CRF synapses can modulate their own receptor(s), and hence the magnitude of the neuroendocrine stress response, is still unknown. The purposes of the present study were therefore: 1) to examine the effects of icv administration of CRF on the gene expression of both CRF receptor types within the rat brain; 2) to analyze the transcriptional activity of CRF via in situ hybridization histochemistry using intronic probe technology; and 3) to verify whether a CRF antagonist can interfere with the influence of exogenous CRF on the expression of CRF and its receptor by using intronic and exonic probe technology. 
Results c-fos mRNA expression in vehicle-and CRF-treated rats
The distribution of the c-fos mRNA in vehicle-treated rats was consistently elevated in several brain regions, such as the cortex, nucleus accumbens, caudate putamen, suprachiasmatic nucleus, dentate gyrus, and areas CAl, CA2, and CA3 of the hippocampus. Moreover, in some animals there was enhanced expression in the cerebral tissue surrounding the guide cannula, and within the piriform area of the cortex and hippocampus ipsilateral to the side of implantation. However, of particular interest to the present study, very low to undetectable levels of the c-fos gene transcript were detected within the PVN of the hypothalamus. After an icv injection of h ,f rCRF, increased expression of c-fos was observed in the CeA, bed nucleus of the stria terminalis, nucleus accumbens, and hippocampal formations. Within the PVN, there was a significant increase in c-fos mRNA, particularly in the parvocellular division representing the primary neurosecretory neurons of the hypothalamic-pituitary-adrenal (HPA) axis, as compared with vehicle-injected rats (Figs. 1 and 2 ). This CRF-induced c-fos expression in the PVN was maximal and significantly elevated over vehicle-treated rats (P < 0.05) at 15 min postinjection, which declined to basal conditions by 60 min after the icv injection. After a pretreatment with the selective CRF antagonist D-Phel', this CRF-induced c-fis expression was effectively blocked in the PVN (Fig. 2) , suggesting the involvement of a CRF receptor. It should be noted that the icv injection of either CRF or the vehicle solution caused an elevated c-fos mRNA expression in the ependymal cell layer (support cells) of the lateral and third ventricles ( Fig. 1 ) and in the cerebral aqueduct. This expression has been accredited as an artifact produced by an increased pressure caused by the icv injection. Parkes et al. (18) reported similar findings for C--OS mRNA expression in the rat PVN after icv injection.
CRF hnRNA expression in vehicle-and CRF-treated rats
The relatively high basal levels of CRF mRNA seen throughout the rat brain renders the task of quantifying and describing discrete changes in mRNA levels difficult. Indeed, whether a higher level of CRF mRNA in a region after a given perturbation or treatment is the result of increased gene expression or an inhibition of the mRNA degradation is speculative at best. However, with the introduction of intronic probe technology, it has become possible to evaluate the transcriptional activity of specific genes within the CNS.
There was no positive signal detected throughout the rat brain after icv injection of the vehicle solution, although in a few rats, the CeA displayed a weak hybridization signal for the CRF hnRNA that was isolated to the side ipsilateral to the cannula (Fig. 3, top) . However, an icv injection of 10 ~1 h/rCRF caused a very intense and significant (P < 0.05) expression of the CRF hnRNA selectively within the parvocellular PVN (Fig. 3) rats. Note the strong hybridization signal in the parvocellular division of the PVN in CRF-treated rats, whereas in the PVN of control rats, the c-f0.s transcript is virtually undetectable. A strong hybridization signal was also detected in the ependymal cells lining the third cerebral ventricle (3V) in both vehicle-and CRF-treated rats (right ofeach panel). This induction is most probably an artifact resulting from the pressure caused by the icv injection of both vehicle and CRF, because this was observed in the cerebral aqueduct and ventricular systems as well. Magnification, X25.
dropping to basal levels by 60 min after CRF administration (Fig. 4) . Moreover, pretreatment with the selective antagonist D-Phe" completely inhibited this CRF-induced increase in CRF transcription (Fig. 4) .
CRF, receptor mRNA expression in vehicle-and CRFtreated rats
As depicted in Table 1 , a moderate to strong hybridization signal for the mRNA encoding CRF, receptor was detected in multiple regions of the brain including the piriform cortex, medial septal nucleus, nucleus of the diagonal band, medial nucleus of the amygdala, basolateral nucleus of the amygdala, arcuate nucleus, subthalamic nucleus, red nucleus, interpeduncular nucleus (central subnucleus), cuneiform nucleus, laterodorsal tegmental nucleus, pontine gray, medial parabrachial nucleus, Purkinje and granule cell layers of the cerebellum, nucleus incertus, medial vestibular nucleus, spinal nucleus of the trigeminal nerve (oral part), nucleus prepositus, principal sensory nucleus of the trigeminal nerve, external cuneate nucleus, spinal nucleus of the trigeminal nerve (interpolar part), lateral reticular nucleus, gracile nucleus, and various layers of the cerebral cortex. Qualitative analysis performed on x-ray films did not reveal notable differences between vehicle-and CRF-treated animals in most of these endogenously expressing sites. In contrast, although vehicle-injected rats exhibited a low to undetect- able expression of the CRF type 1 receptor transcript in the PVN, icv injection of h/ rCRF caused a marked and selective transcription of that gene in this hypothalamic nucleus (Fig.  5) . Unlike the early induction of c-fos mRNA and the CRF hnRNA (Figs. 2 and 4) , exogenous CRF caused a significant increase in the CRF, receptor mRNA signal only at 180 min postinjection (P < 0.05) (Fig. 6) . Furthermore, this CRF-induced activation of the CRF, receptor expression within the PVN was effectively abolished after a pretreatment with the selective CRF antagonist D-Phei' (Fig. 6 ).
CRF,, receptor mRNA expression in vehicle-and CRFtreated rats
Because centrally (icv) administered CRF was capable of selectively targeting the transcription of the CRF type 1 receptor mRNA within the PVN, the question was posed as to whether the transcription of any other CRF receptor types may be induced by exogenous CRF. The hybridization signal for CRF,, mRNA was measured and quantified throughout the rat brain, and it was found that exogenous CRF had no effect on the expression of this receptor (Fig. 7) . Indeed, the hybridization signal for the mRNA encoding the CRF,, in all of the endogenously expressing regions, including the lateral septum, intermediate part [lateral septal nucleus (LSi)] (Fig. 7, top) was not significantly different between vehicle and CRF-treated rats regardless of the time course measured. These regions corroborate well with other studies that have localized CRF,, receptor within the rat brain (24, 32, 33) . However, no convincing hybridization signal was observed in the PVN of vehicle-or CRFinjected rats (Fig. 7, middle 
Discussion
The present study provides evidence that the gene encoding the CRF type 1 receptor is modulated in a positive manner by exogenous CRF selectively within the PVN. Central mRNA within the PVN, whereas vehicle and/or D-Phe"-treated rats displayed low to undetectable levels of CRF, receptor mRNA within this hypothalamic structure. Moreover, CRF-treated rats displayed strong but transient mRNA levels of C-+X within the PVN, which was absent in vehicle-treated rats, corroborating well with other similar studies (17, 18, 34) . Using intronic probe technology, we now show that exogenous CRF activates transcription of CRF selectively within the PVN; the hybridization signal for the CRF hnRNA was observed exclusively in the PVN at 15 min post-CRF injection. Furthermore, the competitive CRF antagonist D-Phe'* was capable of blocking both the CRFinduced CRF hnRNA and C-&S mRNA hybridization signals. Taken together, this study supports the hypothesis of an ultra-short positive feedback loop within the PVN through which CRF may modulate its own biosynthesis as well as that of its type 1 receptor. This may ultimately play an important role in the animal's ability to restore homeostasis during stressful situations.
The theory of a CRF positive feedback on CRF neurosecretory cells during stress was first suggested by Ono and collaborators (19). More recently, Parkes and co-workers (18) demonstrated the CRF mRNA, along with the immediate early genes (IEGs) c-fos and NGFI-B mRNAs, to be increased within the PVN after icv administration of CRF. These findings support the notion of an ultra-short loop positive feedback control of CRF secretion and biosynthesis. The present study confirms the strong neuronal activation of parvocellular neurons, as indicated by a positive c-f& mRNA hy- bridization signal after icv injection of CRF. Moreover, using a selective riboprobe complementary to the rat CRF intron, providing an indication of early transcription, we provide solid evidence that CRF is able to up-regulate its own gene expression selectively within the hypothalamic PVN (Fig. 3) . These results would suggest the existence of CRF-CRF synaptic connections at the level of the PVN, which is supported by anatomical evidence (20, 35) . Alternatively, these CRF terminals may be originating from other CRFergic areas of the brain, stimulated by the icv injection of CRF (36, 37). The use of IEGs such as c-fos as temporally and spatially specific indicators of neuronal activation is well documented (38-40). However, any inferences towards a direct causeand-effect relationship between IEG expression and the target gene under investigation depends on whether there is a functional consensus sequence in the gene's promoter region. The temporal changes in c-fos mRNA and CRF hnRNA seen in this study follow the same pattern (Figs. 2 and 4) ; however, it seems unlikely that c-f& triggered the transcription of neuroendocrine CRF within the PVN. The consensus sequence for the heterodimer formed by c-fos and c-&n, AP-1, is not found on the rat CRF gene promoter (41) This CRF-induced CRF, receptor mRNA expression in the PVN was maximal and significantly elevated over vehicle-treated rats (Veh) (P < 0.05) at 180 min postinjection. However, after pretreatment with the selective CRF antagonist D-Phel'. this CRF-induced CRF tvne 1 recentor mRNA ex&ession was effectively blocked within the PVN. These results represent means t SEM of 3-4 rats. Statistical analysis was performed using a factorial ANOVA (4 X 3) followed by a BonferroniI Dunn post hoc test. *, P < 0.05 from other groups of rats.
ceptor gene still remains to be identified, and whether the AP-1 site can directly target and bind to this promoter is an open question.
As discussed above, the transcription of the CRF type 1 receptor followed by more than 1 h the expression of both CRF hnRNA and c-J&s mRNA in the parvocellular PVN of centrally CRF-injected rats. Pretreatment with CRF antagonist is able to prevent the influence of exogenous CRF and provides the evidence that these phenomena are mediated through a CRF receptor. The time course of induction remains therefore, quite interesting and raises several questions in regard to the physiological relevance of the expression of CRF, receptor in the rat PVN. It is possible that the delayed appearance of the CRF, receptor mRNA may represent a functional adaptation of the HPA axis to better respond to stress. In much the same reasoning as a facilitatory trace left by a preceding stress (42), an increase in the CRF, receptor mRNA within the PVN may be a mode through which the organism prepares itself for a subsequent challenge. Alternatively, the late appearance of CRFi receptor mRNA transcription within the PVN may be a consequence of a long-lasting glucocorticoid feedback on the PVN (43, 44) . Once the feedback inhibition is removed, would there be any increase in the CRF, receptor mRNA within the PVN which, in the present case, is 3 h after the perturbation? This type of feedback is responsible for the tonic suppression of CRF (and vasopressin) by endogenous glucocorticoids (45) (46) (47) (48) . The functional significance of the CRF type 1 receptor has to be clarified, but its presence within the parvocellular PVN during various types of challenges provides CRF2, Receptor mRNA clear anatomical evidence that this stress-related neuropeptide can modulate directly neuroendocrine CRF under stressful conditions. Feedback inhibition of the HPA axis by circulating glucocorticoids is an integral part of the stress response, preventing an over-reaction of the adaptive stress response. Circulating glucocorticoids feedback onto the anterior pituitary to inhibit ACTH release (44), and parvocellular neurosecretory neurons of the hypothalamus to inhibit CRF release (49,, 50) . There are in fact three periods of glucocorticoid effects at both the hypothalamic and pituitary levels (44). A fast, rate-sensitive feedback acts within seconds to inhibit the release of hypothalamic ACTH secretagogues (44, 51). A silent period, during which there is no inhibitory feedback by glucocorticoids, of up to 45 min is representative of the intermediate or delayed feedback (44, 51). Finally, when glucocorticoid levels have been elevated for hours to days, the expression and release of hypothalamic ACTH secretagogues are reduced, which is characteristic of a slow feedback (44, 51). However, both the fast and delayed feedback corticosterone inhibitory mechanisms are blocked after episodes of chronic stress or chronic treatment with corticosterone (43). There would appear to be a stress-induced facilitation to subsequent stimulation of ACTH secretion, explaining why the HPA axis can be normoresponsive to repeated stress; a stress-induced facilitatory trace (42). This facilitatory trace would appear to occur at the level of the PVN because a number of studies have demonstrated CRF to cause a desensitization of the pituitary to subsequent exposure of CRF (52, 53) and this diminishes the pituitary responsiveness to acute stress (54). Indeed, Makino and collaborators (55) have recently shown a decrease in the ability of glucocorticoids to inhibit levels of parvocellular PVN CRF and vasopressin after repeated stress. This corroborates well with the findings of the present study in which we show a very selective increase in transcription of the CRF hnRNA (Fig. 2) and its type 1 receptor mRNA (Fig. 4) selectively within the PVN. Interestingly though, this CRF receptor subtype is reduced in the pituitary by chronic restraint stress (56), whereas treatment of incubated rat anterior pituitary with CRF causes a rapid reduction in CRF, receptor gene expression (57). Our results show that CRF caused an increase in the level of transcription of the CRF, receptor mRNA solely within the PVN that was completely blocked by the selective CRF antagonist D-Phe*'. This effect is quite similar to that observed after either an immune challenge or immobilization stress (28, 58) . Despite the fact that the level of CRF, receptor mRNA was significantly elevated in the PVN after icv CRF injection, no change in CRF,, receptor mRNA was observed in any brain structure (Fig. 7) . It was just recently that this second member of the CRF receptor family was cloned and characterized in the rat (24) and human (25) brains. There is some evidence that, although having a somewhat different distribution pattern vs. the type 1 receptor, the CRF,, receptor mRNA is present in the hypothalamus, particularly in the PVN (21,26). Our results however, were unable to show any convincing hybridization signal for the CRF,, receptor mRNA within the PVN in either control or CRF-treated rats. Furthermore, in areas in which CRF,, receptor mRNA was detected, LSi and ventromedial nucleus of hypothalamus for instance, levels of hybridization were unaltered by CRF treatment nor were they reduced by D-Phe" pretreatment (Fig. 7) . Hence, from these results one can conclude that CRF,, receptor mRNA is not present in any significant levels within the PVN and that CRF appears not to be the principal ligand for this receptor. Indeed, urocortin, the novel CRF /urotensin-like peptide, has been shown to be the primary ligand for this receptor that was localized in the rat brain to regions expressing the CRF,, receptor mRNA and no trace was found in the PVN (33). Clearly, more work needs to be conducted to properly identify the functional role of this CRF receptor type.
In summary, the results from the present study indicate that the CRF type 1 receptor mRNA is modulated in a positive manner by exogenous CRF. We demonstrated that centrally (icv) injected h/rCRF (5 pg/lO ~1) induced a very selective, all be it late, transcription of the gene encoding the CRF, receptor within the PVN that was completely antagonized by a pretreatment with the CRF selective antagonist D-Phel*. This increase in the level of receptor transcription by CRF was restricted to the type 1 receptor subtype because the hybridization signal for the CRF,, receptor mRNA was unaffected in the brain regions in which it was located. Moreover, we confirm previous findings of a CRF-induced neuronal activation of parvocellular neurosecretory cells of the PVN (17, 18) , as assessed by c-fos mRNA expression. This neuronal activation was also associated with an increase in the transcription of PVN-CRF; exogenous CRF caused a rapid and strong induction of the CRF hnRNA selectively in the rat PVN, a phenomenon that was abolished by D-Phel' pretreatment. Taken together, these results provide further evidence for an ultra-short loop positive feedback of CRF within the PVN. This positive feedback of CRF on its own type 1 receptor may represent a functional adaptation of the HPA axis in response to stress. Because CRF diffuses quite readily in brain tissue, it is possible that the administered CRF is acting on other hypothalamic and extrahypothalamic regions that send projections to the PVN, inducing the observed effects. More work therefore, with local injections of CRF within specific nuclei, needs to be done to determine which, if any, regions other than the PVN are involved in these CRF-induced changes in the endocrine hypothalamus. 
